Correspondence 0001493152-23-001011 from OKYO Pharma Ltd (OKYO) (CIK 0001849296) (OKYO)

OKYO Pharma Ltd (OKYO) (CIK 0001849296)
Date: Jan. 10, 2023 · CIK: 0001849296 · Accession: 0001493152-23-001011

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-268675

Date

January 12, 2023

Author

LLC

Form

CORRESP

Company

OKYO Pharma Ltd (OKYO) (CIK 0001849296)

Letter

Re: OKYO Pharma LTD (the “Company”)

January 9, 2023

Via EDGAR

Securities and Exchange Commission

Division of Corporation Finance

F Street, NE

Washington, D.C. 20549

Attn: Tyler Howes

Registration Statement on Form F-1/A

File No. 333-268675

Acceleration Request

Requested Date: January 12, 2023

Requested Time: 5:00 p.m., Eastern Standard Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), ThinkEquity LLC, as representative of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form F-1/A (File No. 333-268675) (the “Registration Statement”) to become effective on Thursday, January 12, 2023, at 5:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

[Signature Page Follows]

Securities and Exchange Commission, p. 2

January 9, 2023

Very
truly yours,
ThinkEquity
LLC

Show Raw Text

CORRESP
1
filename1.htm

January
9, 2023

Via
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, NE

Washington,
D.C. 20549

  Attn:
  Tyler Howes

    Re:
    OKYO
    Pharma LTD (the “Company”)

    Registration
    Statement on Form F-1/A

    File
    No. 333-268675

    Acceleration
    Request

    Requested
    Date: January 12, 2023

    Requested
    Time: 5:00 p.m., Eastern Standard Time

Ladies
and Gentlemen:

In
accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), ThinkEquity LLC, as representative
of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the “Commission”)
take appropriate action to cause the Registration Statement on Form F-1/A (File No. 333-268675) (the “Registration Statement”)
to become effective on Thursday, January 12, 2023, at 5:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.

Pursuant
to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus,
to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We
have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities
Exchange Act of 1934, as amended, to the extent applicable.

[Signature
Page Follows]

Securities
and Exchange Commission, p. 2

January
9, 2023

    Very
    truly yours,

    ThinkEquity
    LLC

    By:

    /s/
    Priyanka Mahajan

    Name:
    Priyanka
Mahajan

    Title:

    Managing
    Director, Investment Banking

    cc:
    Gary
    Jacob, OKYO Pharma Ltd

    Jeffrey
    Fessler, Sheppard, Mullin, Richter & Hampton LLP

    Anthony
    Marsico, Dorsey & Whitney LLP

SecProbe.io